Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Pharmacology

Background:

• Preterm labor is a significant concern in singleton pregnancies.
• Cervical length changes are a key indicator of preterm labor risk.
• 17-alpha-hydroxyprogesterone caproate (17P) is a synthetic progestin with potential tocolytic effects.

Purpose of the Study:

• To evaluate the effect of 17-alpha-hydroxyprogesterone caproate (17P) on cervical length changes in women with preterm labor.
• To determine if 17P treatment can attenuate cervical shortening.

Main Methods:

• A randomized controlled trial involving 60 women with singleton pregnancies hospitalized for preterm labor (25-33+6 weeks gestation).
• Exclusion criteria included rupture of membranes and chorioamnionitis.
• Participants were randomized to observation or 17P (341 mg IM twice weekly until 36 weeks gestation).
• Cervical length was measured via transvaginal ultrasound at discharge and at 7 and 21 days post-discharge.

Main Results:

• Cervical shortening was significantly less in the 17P group compared to the observation group at both 7 days (0.83 mm vs 2.37 mm) and 21 days (2.40 mm vs 4.60 mm) post-discharge (P = .002 for both).
• 17P treatment reduced the risk of cervical shortening by >= 4 mm (OR, 0.18; 95% CI, 0.04-0.66).
• 17P treatment also reduced the risk of preterm delivery (OR, 0.15; 95% CI, 0.04-0.58).

Conclusions:

• Undelivered patients hospitalized for preterm labor experience progressive cervical shortening.
• 17-alpha-hydroxyprogesterone caproate (17P) treatment effectively attenuates this cervical shortening.
• 17P therapy shows promise in managing preterm labor by stabilizing cervical length and reducing delivery risk.